Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Vasiliy Shuvaev"'
Autor:
Ekaterina Motyko, Anna Kirienko, Daria Kustova, Asiyat Rajabova, Olga Uspenskaya, Elena Karyagina, Vasiliy Shuvaev, Sergey Voloshin, Sergey Sidorkevich, Irina Martynkevich
Publikováno v:
HemaSphere, Vol 7, p e0532724 (2023)
Externí odkaz:
https://doaj.org/article/f686d890573c4251b372e474c0cf8758
Autor:
Tatiana Nikitina, Ekena Andreevskaya, Elena Babich, Natalia Bulieva, Olga Vinogradova, Elena Volodicheva, Sergey Voloshin, Natalia Glonina, Sergey Dubov, Natalya Esefieva, Elena Zinina, Maria Ivanova, Tatyana Klitochenko, Anna Kopylova, Alexander Kulagin, Galina Kuchma, Olga LI, Elza Lomaia, Anna Lyamkina, Anait Melikyan, Vladimir Melnichenko, Svetlana Menshakova, Natalia Minaeva, Tatiana Mitina, Elena Morozova, Oksana Ochirova, Alexey Polyakov, Tatiana Pospelova, Andrey Proydakov, Oleg Rukavitsyn, Guzel’ Safuanova, Irina Soubortseva, Mikhail Fominykh, Maria Frolova, Tatiana Shelekhova, Dmitriy Sherstnev, Tatiana Shneider, Vasiliy Shuvaev, Natalia Porfirieva, Esther Oliva, Sam Salek, Tatyana Ionova
Publikováno v:
HemaSphere, Vol 7, p e23759a8 (2023)
Externí odkaz:
https://doaj.org/article/09046401ce7f4663970b72acf4a23c8b
Autor:
Anna Kirienko, Ekaterina Motyko, Daria Kustova, Vasiliy Shuvaev, Elizaveta Efremova, Sergey Sidorkevich, Irina Martynkevich
Publikováno v:
HemaSphere, Vol 7, p e9529428 (2023)
Externí odkaz:
https://doaj.org/article/de45d9958a224fabaf7c7e0f35878798
Autor:
Nadezhda Nemstsveridze, Vasiliy Shuvaev, Irina Martynkevich, Elizaveta Efremova, Ekaterina Mileeva, Ekaterina Motyko, Anna Kirienko, Daria Kustova, Sergey Sidorkevich
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04db61122cbe2362b7c6571e622d6c46
https://doi.org/10.1016/s2152-2650(22)00911-9
https://doi.org/10.1016/s2152-2650(22)00911-9
Autor:
Nadezhda Nemstsveridze, Vasiliy Shuvaev, Irina Martynkevich, Elizaveta Efremova, Ekaterina Mileeva, Ekaterina Motyko, Anna Kirienko, Daria Kustova, Sergey Sidorkevich
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S296
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7d505e57be2a9d36c59dbdf8925c7fb
https://doi.org/10.1016/s2152-2650(22)01380-5
https://doi.org/10.1016/s2152-2650(22)01380-5
Autor:
Anna Petrova, Vasiliy Shuvaev, Hunan Julhakyan, Anastasiya Bykova, Tatyana Ionova, Anna G. Turkina, Galina Gusarova, Irina Nemchenko, Nikolay Tsyba, Oleg Shukhov, Ekaterina Chelysheva, Mikhail Fominykh, Irina Martynkevich
Publikováno v:
Clinical lymphoma, myelomaleukemia. 20(5)
We aimed to characterize withdrawal syndrome (WS) and evaluate factors associated with its development in the prospective clinical study RU-SKI in patients with chronic myeloid leukemia with deep molecular response who discontinued tyrosine kinase in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70f0fb4bc0d18ab0497509c16a1cf9b
https://pubmed.ncbi.nlm.nih.gov/32146103
https://pubmed.ncbi.nlm.nih.gov/32146103
Autor:
Sergey M. Kulikov, Anastasia Bykova, Anna Kersilova, L. L. Vysotskaya, Olga Pospelova, Anna G. Turkina, Irina Martynkevich, Anatoly Golenkov, Andrey Sudarikov, Vasiliy Shuvaev, Galina Gusarova, Michael Fominykh, Margarita Gurianova, Oleg Shukhov, Anna Petrova, Nikolay Tsyba, A O Abdullaev, Hunan Julhakyan, Irina Nemchenko, Ekaterina Chelysheva, Polina Poshivay Agnia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S239
Introduction Duration of treatment with tyrosine kinase inhibitors (TKI) is an important favorable prognostic factor for treatment-free remission (TFR) and deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia (CML). Aim To an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd86e6379151945bda5746e4c03b1c4d
https://doi.org/10.1016/s2152-2650(20)30824-7
https://doi.org/10.1016/s2152-2650(20)30824-7
Autor:
Irina Martinkevich, Natalia Ilina, Andrey Zaritskey, Elena Karyagina, Natalia Lazorko, Elza Lomaia, Elena Usacheva, Vera Udalieva, Ekaterina Romanova, Irina Zotova, Tatiana Shneider, Eugenia Sbityakova, Alla Abdulkadyrova, Vasiliy Shuvaev, Kudrat Abdulkadyrov, Elena Machulaitene, Irina Kholopova
Publikováno v:
Blood. 120:4432-4432
Abstract 4432 Background: The incidence of chronic myeloid leukemia (CML), reported from some population based registries, varies significantly. CML is known as age-dependent disease, so population age structure may strongly influent on the data. For
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17fd5ff81f2a344215a0c7f327fc80aa
https://doi.org/10.1182/blood.v120.21.4432.4432
https://doi.org/10.1182/blood.v120.21.4432.4432
Autor:
Elena Koryagina, Irina Zotova, Elza Lomaia, Natalia Ilina, Vasiliy Shuvaev, Andrey Zaritskey, Zvenyslava Masliak, Irina Dyagil, Natalia Lazorko, Natalia Babkina, Irina Dmitrenko, T. Perekhrestenko, Elena Machulaitene, Svetlana Stepanova, Ekaterina Poznyak, Elena Usacheva, Kudrat Abdulkadirov, Irina Martinkevich, Eugenia Sbityakova, Ekaterina Romanova, Alla Abdulkadirova, Elena Goryunova, Maria Ivanova, Vera Udalieva, Tatiana Shneider
Publikováno v:
Blood. 118:4452-4452
Abstract 4452 Imatinib (IM) is now used world-wide as a first line chronic myeloid leukemia (CML) treatment. Although some time lack may exist between diagnosis and IM treatment. Earlier (Blood 2009, 114: Abstract 4278) we have shown that in CML chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddb01716cabed8d713333cbe913c4f27
https://doi.org/10.1182/blood.v118.21.4452.4452
https://doi.org/10.1182/blood.v118.21.4452.4452
Autor:
Dgariyat Shikhbabaeva, Elza Lomaia, Elena Usacheva, Ekaterina Romanova, Elena Machulaitene, Natalia Ilina, Irina Martynkevich, Alla Abdulkadyrova, Vasiliy Shuvaev, Evgenia Salamatova, Kudrat Abdulkadyrov, Irina Zotova, Tatiana Shneider, Vera Udalieva, Ekaterina Poznyak, Maria Ivanova, Natalia Lazorko, Elena Koryagina, Svetlana Stepanova, Andrey Zaritskey
Publikováno v:
Blood. 116:4476-4476
Abstract 4476 At present, the main goal of chronic myeloid leukemia (CML) therapy is to obtain complete cytogenetic response (CCyR) which is strongly associated with patient's survival. The second main factor for good prognosis after CCyR achievement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76be59190c6a2d4e5ea90a0bae96377c
https://doi.org/10.1182/blood.v116.21.4476.4476
https://doi.org/10.1182/blood.v116.21.4476.4476